Search

Your search keyword '"Michelson, Eric L."' showing total 429 results
Start Over "Michelson, Eric L."
429 results on '"Michelson, Eric L."'

2. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy

Author

Scirica, Benjamin M., Cannon, Christopher P., Emanuelsson, Håkan, Michelson, Eric L., Harrington, Robert A., Husted, Steen, James, Stefan, Katus, Hugo, Pais, Prem, Raev, Dimitar, Spinar, Jindrich, Steg, Ph. Gabriel, Storey, Robert F., and Wallentin, Lars

Published
2011
Full Text
View/download PDF

12. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Author

Ducharme, Anique, Swedberg, Karl, Pfeffer, Marc A., Cohen-Solal, Alain, Granger, Christopher B., Maggioni, Aldo P., Michelson, Eric L., McMurray, John J.V., Olsson, Lars, Rouleau, Jean L., Young, James B., Olofsson, Bertil, Puu, Margareta, and Yusuf, Salim

Subjects
Atrial fibrillation -- Prevention, Heart failure -- Complications and side effects, Heart failure -- Care and treatment, Mortality -- Evaluation, Cardiac patients -- Care and treatment, Angiotensin -- Receptors, Angiotensin -- Physiological aspects, Angiotensin -- Research, Health
Published
2006

13. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM)--added trial

Author

McMurray, John J.V., Young, James B., Dunlap, Mark E., Granger, Christopher B., Hainer, James, Michelson, Eric L., Earle, Steven, Olofsson, Bertil, Ostergren, Jan, Yusuf, Salim, Swedberg, Karl, and Pfeffer, Marc A.

Subjects
Angiotensin converting enzyme -- Research, Angiotensin converting enzyme -- Physiological aspects, Heart failure -- Research, Heart failure -- Care and treatment, Mortality -- Evaluation, Candesartan -- Research, Candesartan -- Physiological aspects, Health
Published
2006

14. Feasibility of treating prehypertension with an angiotensin-receptor blocker

Author

Julius, Stevo, Nesbitt, Shawna, Egan, Brent M., Weber, Michael A., Oparil, Suzanne, Schork, Anthony M., Michelson, Eric L., Kaciroti, Niko, Black, Henry R., Grimm, Richard H., and Messerli, Franz H.

Subjects
Hypertension -- Drug therapy, Candesartan -- Dosage and administration, Candesartan -- Research
Abstract

A test was conducted to investigate whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension. Treatment of prehypertension with candesartan appeared to be well tolerated and reduced the risk of incident hypertension indicating that pharmacological treatment of hypertension is feasible.

Published
2006

15. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial

Author

Granger, Bradi B., Swedberg, Karl, Ekman, Inger, Granger, Christopher B., Olofsson, Bertil, McMurray, John J.V., Yusuf, Salim, Michelson, Eric L., and Pfeffer, Marc A.

Subjects
Heart failure -- Risk factors, Heart failure -- Complications and side effects, Heart failure -- Care and treatment, Heart failure -- Analysis, Heart failure -- Patient outcomes
Published
2005

16. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure

Author

Demers, Catherine, McMurray, John J.V., Swedberg, Karl, Pfeffer, Marc A., Granger, Christopher B., Olofsson, Bertil, McKelvie, Robert S., Ostergren, Jan, Michelson, Eric L., Johansson, Peter A., Duolao Wang, and Yusuf, Salim

Subjects
Candesartan -- Dosage and administration, Candesartan -- Complications and side effects, Heart attack -- Drug therapy, Cardiac patients -- Medical examination
Abstract

A program is carried out with heart patients to study the effect of the angiotensin receptor blocker candesartan on myocardial infarction (MI) and other coronary disorders. Findings prove that the danger of the combined outcome of cardiovascular death or nonfatal MI markedly decreases with candesartan.

Published
2005

19. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction

Author

Christian, Jennifer B., Finkle, John K., Ky, Bonnie, Douglas, Pamela S., Gutstein, David E., Hockings, Paul D., Lainee, Pierre, Lenihan, Daniel J., Mason, Jay W., Sager, Philip T., Todaro, Thomas G., Hicks, Karen A., Kane, Robert C., Ko, Hon-Sum, Lindenfeld, JoAnn, Michelson, Eric L., Milligan, James, Munley, Jiefen Y., Raichlen, Joel S., Shahlaee, Amir, Strnadova, Colette, Ye, Brenda, and Turner, Rick J.

Published
2012
Full Text
View/download PDF

22. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

Author

Granger, Christopher B., Ertl, Georg, Kuch, Jerzy, Maggioni, Aldo P., McMurray, John, Rouleau, Jean-Lucien, Stevenson, Lynn Warner, Swedberg, Karl, Young, James, Yusuf, Salim, Califf, Robert M., Bart, Bradley A., Held, Peter, Michelson, Eric L., Sellers, Mary Ann, Ohlin, Gunilla, Sparapani, Rodney, and Pfeffer, Marc A.

Subjects
Angiotensin II receptor blockers -- Evaluation, Congestive heart failure -- Drug therapy, Health
Published
2000

23. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme

Author

Chang, Su Min, Granger, Christopher B., Johansson, Peter A., Kosolcharoen, Peter, McMurray, John J.V., Michelson, Eric L., Murray, David R., Olofsson, Bertil, Pfeffer, Marc A., Solomon, Scott D., Swedberg, Karl, Yusuf, Salim, and Dunlap, Mark E.

Published
2010
Full Text
View/download PDF

38. Thrombolytic therapy of acute myocardial infarction: keeping the unfulfilled promises

Author

Doorey, Andrew J., Michelson, Eric L., and Topol, Eric J.

Subjects
Thrombolytic drugs -- Health aspects, Heart attack -- Drug therapy
Abstract

Thrombolytic therapy may be used to prevent another heart attack in patients who have already suffered a severe heart attack. Thrombolytic therapy is treatment with different drugs to break up blood clots. A survey of the medical literature found that thrombolytic therapy can significantly decrease the number of complications and deaths among patients who have suffered a severe heart attack. Many patients who would benefit from this type of treatment do not receive it for a variety of reasons. Patients with high blood pressure or who have received cardiopulmonary resuscitation (CPR) often do not receive thrombolytic therapy, even though these conditions only slightly decrease their chance of benefiting from treatment. Elderly patients who have had a heart attack should not excluded from treatment on the basis on their age.

Published
1992

39. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the Study of Patients Intolerant of Converting Enzyme inhibitors registry

Author

Shah, Monica R., Granger, Christopher B., Bart, Bradley A., McMurray, John J.V., Petrie, Mark C., Michelson, Eric L., Tudor, Gail E., Swedberg, Karl, Stevenson, Lynne W., Califf, Robert M., and Pfeffer, Marc A.

Subjects
ACE inhibitors -- Health aspects, Heart failure -- Drug therapy, Sex factors in disease -- Research, Health, Health care industry
Published
2000

46. Effects of encainide and metabolizer phenotype on ventricular conduction during exercise

Author

Karalis, Dean G., Nydegger, Charles, Porter, R. Stephen, Carver, Joseph, Pina, Ileana L., Kutalek, Steven P., and Michelson, Eric L.

Subjects
Anti-arrhythmia drugs -- Physiological aspects, Heart conduction system -- Physiological aspects, Encainide hydrochloride -- Physiological aspects, Health
Abstract

Cardiac arrhythmias are a prevalent and potentially very dangerous heart disorder in which one or more chambers of the heart beats in an irregular pattern. A number of drugs, including encainide, are used to treat arrhythmias. Among Caucasians, there seem to be two groups of patients distinguishable on the basis of their ability to metabolize this drug; so-called extensive metabolizers rapidly convert encainide to its derivative form, while poor metabolizers do so at a much slower rate. Encainide can produce a marked slowing of electrical conduction in the heart, and this effect varies in relation to the heart rate. The two metabolites are much more potent than the parent compound in this regard. Thus, it might be expected that poor and extensive metabolizers would differ with respect to rate-dependent changes in cardiac conduction following encainide administration. To test this hypothesis, nine patients who were taking encainide for cardiac arrhythmias were studied. Cardiac conduction was measured by monitoring the duration of a characteristic segment of the electrocardiogram (QRS duration). Patients were subjected to exercise testing in order to increase their heart rate, and were analyzed by grouping them into subsets of poor and extensive metabolizers. Among extensive metabolizers, in whom encainide would presumably be rapidly metabolized to the more active form, exercise induced a significant increase in the duration of the QRS segment. In poor metabolizers, in whom the drug would remain in its less-active form, there was no such increase in the QRS segment. In control subjects (who did not receive any drug) there was no increase in QRS duration with exercise. The increase in the QRS duration in some patients (extensive metabolizers) may represent one of the means by which this anti-arrhythmic drug can, in some cases, actually exacerbate arrhythmia. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results